Financial Contrast: Zynex (NASDAQ:ZYXI) vs. Bluejay Diagnostics (NASDAQ:BJDX)

Bluejay Diagnostics (NASDAQ:BJDX) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Profitability

This table compares Bluejay Diagnostics and Zynex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Zynex	-68.35%	-804.30%	-36.67%

Volatility and Risk

Bluejay Diagnostics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Institutional and Insider Ownership

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bluejay Diagnostics and Zynex”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.09
Zynex	$108.20 million	0.04	$2.99 million	($2.43)	-0.05

Zynex has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Bluejay Diagnostics and Zynex, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1	0	0	0	1.00
Zynex	1	0	0	0	1.00

Summary

Zynex beats Bluejay Diagnostics on 8 of the 10 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About Zynex

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.